annual CFO:
$184.15M+$254.39M(+362.19%)Summary
- As of today (June 28, 2025), PTGX annual cash flow from operations is $184.15 million, with the most recent change of +$254.39 million (+362.19%) on December 31, 2024.
- During the last 3 years, PTGX annual CFO has risen by +$292.02 million (+270.72%).
- PTGX annual CFO is now at all-time high.
Performance
PTGX Cash from operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFO:
$125.36M+$154.54M(+529.65%)Summary
- As of today (June 28, 2025), PTGX quarterly cash flow from operations is $125.36 million, with the most recent change of +$154.54 million (+529.65%) on March 1, 2025.
- Over the past year, PTGX quarterly CFO has increased by +$152.79 million (+557.05%).
- PTGX quarterly CFO is now -53.33% below its all-time high of $268.62 million, reached on June 30, 2024.
Performance
PTGX quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFO:
$336.94M+$152.79M(+82.97%)Summary
- As of today (June 28, 2025), PTGX TTM cash flow from operations is $336.94 million, with the most recent change of +$152.79 million (+82.97%) on March 1, 2025.
- Over the past year, PTGX TTM CFO has increased by +$400.26 million (+632.15%).
- PTGX TTM CFO is now at all-time high.
Performance
PTGX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
PTGX Cash from operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +362.2% | +557.0% | +632.1% |
| 3 y3 years | +270.7% | +432.8% | +388.5% |
| 5 y5 years | +543.5% | +891.0% | +927.6% |
PTGX Cash from operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +270.3% | -53.3% | +432.8% | at high | +383.6% |
| 5 y | 5-year | at high | +270.3% | -53.3% | +432.8% | at high | +383.6% |
| alltime | all time | at high | +270.3% | -53.3% | +432.8% | at high | +383.6% |
PTGX Cash from operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $125.36M(-529.6%) | $336.94M(+83.0%) |
| Dec 2024 | $184.15M(-362.2%) | -$29.18M(+4.7%) | $184.15M(-20.0%) |
| Sep 2024 | - | -$27.86M(-110.4%) | $230.29M(-0.5%) |
| Jun 2024 | - | $268.62M(-1079.3%) | $231.54M(-465.7%) |
| Mar 2024 | - | -$27.43M(-261.7%) | -$63.32M(-9.8%) |
| Dec 2023 | -$70.24M(-35.0%) | $16.96M(-163.7%) | -$70.24M(-40.9%) |
| Sep 2023 | - | -$26.61M(+1.4%) | -$118.83M(+1.2%) |
| Jun 2023 | - | -$26.24M(-23.6%) | -$117.42M(+12.0%) |
| Mar 2023 | - | -$34.35M(+8.6%) | -$104.82M(-3.1%) |
| Dec 2022 | -$108.14M(+0.3%) | -$31.64M(+25.5%) | -$108.14M(+4.5%) |
| Sep 2022 | - | -$25.20M(+84.8%) | -$103.44M(-3.1%) |
| Jun 2022 | - | -$13.63M(-63.8%) | -$106.71M(-8.6%) |
| Mar 2022 | - | -$37.67M(+39.8%) | -$116.78M(+8.3%) |
| Dec 2021 | -$107.86M(+48.8%) | -$26.94M(-5.4%) | -$107.86M(+8.1%) |
| Sep 2021 | - | -$28.47M(+20.1%) | -$99.79M(+13.9%) |
| Jun 2021 | - | -$23.70M(-17.6%) | -$87.61M(+2.6%) |
| Mar 2021 | - | -$28.76M(+52.4%) | -$85.39M(+17.8%) |
| Dec 2020 | -$72.48M(+74.5%) | -$18.87M(+15.8%) | -$72.48M(+6.7%) |
| Sep 2020 | - | -$16.29M(-24.2%) | -$67.91M(+3.1%) |
| Jun 2020 | - | -$21.48M(+35.6%) | -$65.86M(+61.8%) |
| Mar 2020 | - | -$15.85M(+10.9%) | -$40.71M(-2.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | -$41.53M(-16.9%) | -$14.29M(+0.3%) | -$41.53M(+11.1%) |
| Sep 2019 | - | -$14.25M(-488.2%) | -$37.37M(+15.3%) |
| Jun 2019 | - | $3.67M(-122.0%) | -$32.40M(-37.0%) |
| Mar 2019 | - | -$16.66M(+64.4%) | -$51.47M(+3.1%) |
| Dec 2018 | -$49.95M(-1390.0%) | -$10.13M(+9.3%) | -$49.95M(-7.4%) |
| Sep 2018 | - | -$9.28M(-39.8%) | -$53.96M(+1255.5%) |
| Jun 2018 | - | -$15.40M(+1.7%) | -$3.98M(+337.5%) |
| Mar 2018 | - | -$15.14M(+7.0%) | -$910.00K(-123.5%) |
| Dec 2017 | $3.87M(-112.9%) | -$14.15M(-134.8%) | $3.87M(-53.6%) |
| Sep 2017 | - | $40.70M(-430.2%) | $8.34M(-121.2%) |
| Jun 2017 | - | -$12.33M(+19.0%) | -$39.34M(+12.1%) |
| Mar 2017 | - | -$10.36M(+7.0%) | -$35.09M(+17.1%) |
| Dec 2016 | -$29.97M(+108.4%) | -$9.68M(+38.7%) | -$29.97M(+19.7%) |
| Sep 2016 | - | -$6.98M(-13.5%) | -$25.03M(+14.7%) |
| Jun 2016 | - | -$8.07M(+54.1%) | -$21.82M(+26.9%) |
| Mar 2016 | - | -$5.24M(+10.6%) | -$17.19M(+19.5%) |
| Dec 2015 | -$14.38M(+85.8%) | -$4.74M(+25.7%) | -$14.38M(+49.1%) |
| Sep 2015 | - | -$3.77M(+9.4%) | -$9.65M(+64.1%) |
| Jun 2015 | - | -$3.44M(+41.6%) | -$5.88M(+141.6%) |
| Mar 2015 | - | -$2.43M | -$2.43M |
| Dec 2014 | -$7.74M | - | - |
FAQ
- What is Protagonist Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Protagonist Therapeutics?
- What is Protagonist Therapeutics annual CFO year-on-year change?
- What is Protagonist Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Protagonist Therapeutics?
- What is Protagonist Therapeutics quarterly CFO year-on-year change?
- What is Protagonist Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Protagonist Therapeutics?
- What is Protagonist Therapeutics TTM CFO year-on-year change?
What is Protagonist Therapeutics annual cash flow from operations?
The current annual CFO of PTGX is $184.15M
What is the all time high annual CFO for Protagonist Therapeutics?
Protagonist Therapeutics all-time high annual cash flow from operations is $184.15M
What is Protagonist Therapeutics annual CFO year-on-year change?
Over the past year, PTGX annual cash flow from operations has changed by +$254.39M (+362.19%)
What is Protagonist Therapeutics quarterly cash flow from operations?
The current quarterly CFO of PTGX is $125.36M
What is the all time high quarterly CFO for Protagonist Therapeutics?
Protagonist Therapeutics all-time high quarterly cash flow from operations is $268.62M
What is Protagonist Therapeutics quarterly CFO year-on-year change?
Over the past year, PTGX quarterly cash flow from operations has changed by +$152.79M (+557.05%)
What is Protagonist Therapeutics TTM cash flow from operations?
The current TTM CFO of PTGX is $336.94M
What is the all time high TTM CFO for Protagonist Therapeutics?
Protagonist Therapeutics all-time high TTM cash flow from operations is $336.94M
What is Protagonist Therapeutics TTM CFO year-on-year change?
Over the past year, PTGX TTM cash flow from operations has changed by +$400.26M (+632.15%)